Tumor Immune Microenvironment Analysis and MRI Results of a Phase II Trial Investigating Tislelizumab (T) in the Neoadjuvant Treatment of High-Risk Upper Tract Urothelial Carcinoma (UTUC).
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要